TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

• Published in: International journal of molecular sciences Vol. 22; no. 20; p. 10930
• Main Authors: Guo, Shuai, Bai, Xue, Shi, Sai, Deng, Yawen, Kang, Xianjiang, An, Hailong
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.10.2021; MDPI
• Subjects: Animals; Anoctamin-1 - antagonists & inhibitors; Anoctamin-1 - metabolism; Antineoplastic Agents, Phytogenic - chemistry; Antineoplastic Agents, Phytogenic - metabolism; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Apoptosis; Apoptosis - drug effects; Binding Sites; Cancer therapies; Cell growth; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; Chemotherapy; Homoharringtonine - chemistry; Homoharringtonine - metabolism; Homoharringtonine - pharmacology; Homoharringtonine - therapeutic use; Humans; Leukemia; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Medical prognosis; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Mutagenesis; Proteins; Radiation therapy; Signal transduction; Software; Transplantation, Heterologous; Wound healing; Beijing China; Grand Island New York; United States > US; China; homoharringtonine; TMEM16A; inhibitor; drug target; lung adenocarcinoma

Lung cancer has the highest rate of incidence and mortality among all cancers. Most chemotherapeutic drugs used to treat lung cancer cause serious side effects and are susceptible to drug resistance. Therefore, exploring novel therapeutic targets for lung cancer is important. In this study, we evalu...